Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

OBJECTIVE: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunise...

Descripción completa

Detalles Bibliográficos
Autores principales: Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Azaro, Analia, Seoane, Joan, Braña, Irene, Sicart, Elisabet, Miles, Colin, Lahn, Michael M, Mitchell, Malcolm I, Rodon, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Just Medical Media Limited 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147053/
https://www.ncbi.nlm.nih.gov/pubmed/27990167
http://dx.doi.org/10.7573/dic.212303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147053/
https://www.ncbi.nlm.nih.gov/pubmed/27990167
http://dx.doi.org/10.7573/dic.212303

Ejemplares similares